Core Insights - MicroPort Robotics-B (02252) has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment for domestic surgical robots [1][2] Group 1: Company Developments - The approval of UniPathTM increases the number of products approved for commercialization in the surgical robot sector to seven, making the company the first and only one globally to achieve commercialization across all five major categories of surgical robots [1] - The company is building a comprehensive ecosystem of domestic surgical robots characterized by systematic innovation and platform capabilities, which is accelerating towards large-scale development [1] Group 2: Industry Impact - The bronchoscopic surgical robot represents a critical technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions," and is one of the fastest-growing smart minimally invasive diagnostic and therapeutic platforms in the respiratory intervention field [2] - UniPathTM integrates key technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing procedures on small lesions in dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]